MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, trading under the ticker HLXA, is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC merger completed in 2022, operating in the immunology and inflammation therapeutics sector. The company is focused on its lead program sonelokimab, a nanobody targeting conditions including psoriatic arthritis and hidradenitis suppurativa. MoonLake filed an 8-K current report with the SEC on June 6, 2025, continuing its public-company disclosure obligations as a post-merger entity. For full filing history, deal terms, sponsor details, and real-time SPAC data on MoonLake Immunotherapeutics and thousands of other transactions, sign up for SpacDesk.